Navigation Links
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Trovagene, Inc.  (NASDAQ: TROV), a transrenal molecular diagnostic company, today announced the closing of a private placement consisting of 940,000 units at a purchase price of $4.00 per unit, with each unit consisting of one share of unregistered common stock and one warrant to purchase one share of common stock. The gross proceeds to Trovagene from this offering are approximately $3.76 million. The warrants are exercisable for five years from the date of closing at an exercise price of $5.32 per share.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Trovagene intends to use the net proceeds from this private placement offering to fund its research and development activities, and for working capital and other general corporate purposes.

"This private placement is well timed to provide Trovagene with sufficient capital to facilitate the availability of transrenal oncogene mutation testing to clinicians through our diagnostic laboratory," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene.  "The Company now has cash in excess of $10 million, which we expect will be sufficient to fund our operations well into 2014."

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of the Company. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.Contact Trovagene, Inc. Financial

Investor RelationsStephen Zaniboni

Amy CaterinaChief Financial Officer

Investor RelationsTrovagene, Inc.

Trovagene, Inc.858-952-7594

858-952-7593szaniboni@trovagene.com 

acaterina@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
2. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
3. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
4. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
5. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
8. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
9. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
10. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
11. Vasomedical Announces Financial Results for the Third Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... solutions, today announced that it will be presenting at the 7th ... AM PT. Erez Raphael , CEO, of DarioHealth will be ... will be held on June 6th & 7th, 2017 at the ... the small / micro-cap space. ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... 2017 , ... Connance, a leading provider of healthcare predictive ... analytics drive reimbursement optimization, with a focus on denial management and claims statusing, ... traditional approach to denied and underpaid claims leaves money on the table and ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... assessments and consulting services, has published a new eBook titled “ 5 Questions ... Bridge, MSc, Associate Research Analyst on the Genetic Test Evaluation (GTE) team, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos ... and a host of new options for today’s modern senior. Brazos Towers at ... active, independent lifestyle they love while offering them the services to support that lifestyle ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. ... Cincinnati, OH for leading-edge care, whether or not they have a referral. Dr. ... BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting the ...
(Date:6/20/2017)... ... June 20, 2017 , ... This ... program focused on finding product improvements that could reduce the occurrence of ... when they need help breathing or to provide medication. Sometimes, patient movement can ...
Breaking Medicine News(10 mins):